Chemours shares slump as top executives put on leave, results delayed again

Go back to Chemours shares slump as top executives put on leave, results delayed again

BMO Capital Downgrades Chemours (CC) to Underperform

February 29, 2024 7:59 AM EST

BMO Capital analyst John McNulty downgraded Chemours (NYSE: CC) from Market Perform to Underperform with a price target of $19.00 (from $45.00)

The analyst comments "Following a two-week delay in their reporting, Chemours has announced a further delay in filing their results and... More